{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-248461","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.017888+00:00","generated_at":"2026-06-10T06:20:03.894396+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aadi appoints Dave Lennon as President and CEO; base salary $640K, option for 490K shares","bullets":["David J. Lennon appointed President and CEO, effective Oct 2, 2023; Scott Giacobello returns to CFO role.","Compensation: $640,000 base salary, up to 60% annual bonus, $240,000 sign-on (cash + RSUs), option for 490,000 shares.","Board increased from 8 to 9; Lennon appointed as Class II director. Company adopted 2023 Inducement Plan reserving 600,000 shares.","Press release highlights Lennon’s Novartis background and FYARRO pipeline expansion into endometrial, neuroendocrine cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-248461","json":"https://secwatch.observer/filing/0001193125-23-248461.json","markdown":"https://secwatch.observer/filing/0001193125-23-248461.md","text":"https://secwatch.observer/filing/0001193125-23-248461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/d561858d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:20:03.894396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a22a282e52","claim":"David J. Lennon was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “ Board ”) of Aadi Bioscience, Inc. (the “ Company ”) appointed David J. Lennon, Ph.D., to serve as the Company’s President and Chief Executive Officer and principal executive officer, effective as of October 2, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b8bbe2125e","claim":"Scott Giacobello changed role as Chief Financial Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Mr. Giacobello has served as the Company’s Interim CEO and President and principal executive officer since March 15, 2023, and will continue to serve as the Company’s Chief Financial Officer, a position he has held since November 2021, following Dr. Lennon’s appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"continued"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e2cccf9220","claim":"David J. Lennon was appointed as Class II Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the Board increased the Board’s size from eight (8) to nine (9) directors and appointed Dr. Lennon to fill the resulting vacancy","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}